Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

47 results
Filters applied: . Clear all
Page 1
Is high-risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors.
Whittle SB, Smith V, Silverstein A, Parmeter M, Minard CG, Bernhardt MB, Zage PE, Venkatramani R, Nuchtern JG, Heczey A, Russell HV, Shohet JM, Foster JH. Whittle SB, et al. Among authors: shohet jm. Pediatr Blood Cancer. 2020 Oct;67(10):e28417. doi: 10.1002/pbc.28417. Epub 2020 Jul 30. Pediatr Blood Cancer. 2020. PMID: 32729196 Free PMC article. Clinical Trial.
MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma.
Agarwal S, Milazzo G, Rajapakshe K, Bernardi R, Chen Z, Barbieri E, Koster J, Perini G, Coarfa C, Shohet JM. Agarwal S, et al. Among authors: shohet jm. Oncotarget. 2018 Apr 17;9(29):20323-20338. doi: 10.18632/oncotarget.24859. eCollection 2018 Apr 17. Oncotarget. 2018. PMID: 29755654 Free PMC article.
EWS-FLI1 and RNA helicase A interaction inhibitor YK-4-279 inhibits growth of neuroblastoma.
Sun W, Rojas Y, Wang H, Yu Y, Wang Y, Chen Z, Rajapakshe K, Xu X, Huang W, Agarwal S, Patel RH, Woodfield S, Zhao Y, Jin J, Zhang H, Major A, Hicks MJ, Shohet JM, Vasudevan SA, Coarfa C, Yang J, Nuchtern JG. Sun W, et al. Among authors: shohet jm. Oncotarget. 2017 Oct 19;8(55):94780-94792. doi: 10.18632/oncotarget.21933. eCollection 2017 Nov 7. Oncotarget. 2017. PMID: 29212266 Free PMC article.
p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy.
Moreno-Smith M, Lakoma A, Chen Z, Tao L, Scorsone KA, Schild L, Aviles-Padilla K, Nikzad R, Zhang Y, Chakraborty R, Molenaar JJ, Vasudevan SA, Sheehan V, Kim ES, Paust S, Shohet JM, Barbieri E. Moreno-Smith M, et al. Among authors: shohet jm. Clin Cancer Res. 2017 Nov 1;23(21):6629-6639. doi: 10.1158/1078-0432.CCR-17-0668. Epub 2017 Aug 18. Clin Cancer Res. 2017. PMID: 28821555 Free PMC article.
Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma.
Bogen D, Wei JS, Azorsa DO, Ormanoglu P, Buehler E, Guha R, Keller JM, Mathews Griner LA, Ferrer M, Song YK, Liao H, Mendoza A, Gryder BE, Sindri S, He J, Wen X, Zhang S, Shern JF, Yohe ME, Taschner-Mandl S, Shohet JM, Thomas CJ, Martin SE, Ambros PF, Khan J. Bogen D, et al. Among authors: shohet jm. Oncotarget. 2015 Nov 3;6(34):35247-62. doi: 10.18632/oncotarget.6208. Oncotarget. 2015. PMID: 26497213 Free PMC article.
Reactivation of p53 via MDM2 inhibition.
Kim ES, Shohet JM. Kim ES, et al. Among authors: shohet jm. Cell Death Dis. 2015 Oct 22;6(10):e1936. doi: 10.1038/cddis.2015.302. Cell Death Dis. 2015. PMID: 26492369 Free PMC article. No abstract available.
47 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page